--- title: "Arcturus Therapeutics Holdings IncQ) expected to post a loss of 90 cents a share - Earnings Preview" description: "Arcturus Therapeutics Holdings IncQ) is projected to report a loss of 90 cents per share and a 55% decline in quarterly revenue to $22.435 million for the period ending June 30, 2025. The average anal" type: "news" locale: "en" url: "https://longbridge.com/en/news/251248572.md" published_at: "2025-08-01T20:21:05.000Z" --- # Arcturus Therapeutics Holdings IncQ) expected to post a loss of 90 cents a share - Earnings Preview > Arcturus Therapeutics Holdings IncQ) is projected to report a loss of 90 cents per share and a 55% decline in quarterly revenue to $22.435 million for the period ending June 30, 2025. The average analyst rating remains "buy" with a median 12-month price target of $48.00, significantly above its last closing price of $12.21. Recent quarterly performances show a mix of beats and misses against estimates, with the latest earnings estimate unchanged over the past three months. - Arcturus Therapeutics Holdings Inc (ARCT.OQ) (ARCT.O) is expected to show a fall in quarterly revenue when it reports results on August 4 (estimated) for the period ending June 30 2025 - The San Diego California-based company is expected to report a 55.0% decrease in revenue to $22.435 million from $49.86 million a year ago, according to the mean estimate from 9 analysts, based on LSEG data. - ​LSEG’s mean analyst estimate for Arcturus Therapeutics Holdings Inc is for a loss of 90 cents per share. - The current average analyst rating on the shares is “buy” and the breakdown of recommendations is 12 “strong buy” or “buy,” no “hold” and no “sell” or “strong sell.” - The mean earnings estimate of analysts was unchanged in the last three months. ​ - Wall Street’s median 12-month price target for Arcturus Therapeutics Holdings Inc is $48.00, about 74.6% above its last closing price of $12.21 Previous quarterly performance (using preferred earnings measure in US dollars). ​ ### QUARTER STARMINESM LSEG IBES ACTUAL BEAT, SURPRI ### ENDING ARTESTIMAT ESTIMATE MET, SE % ### E® MISSED Mar. 31 2025 -1.26 -1.33 -0.52 Beat 60.9 Dec. 31 2025 -0.52 -0.55 -1.11 Missed -102.2 Sep. 30 2024 -1.23 -1.22 -0.26 Beat 78.6​ Jun. 30 2024 -1.51 -1.60 -0.64 Beat 60 ​​Mar. -1.21 -1.19 -1.00 Beat 15.9 31 2024 Dec. 31 2023 -0.60 -0.99 -0.32 Beat 67.7​ Sep. 30 2023 -1.72 -1.69 -0.61 Beat 63.9 Jun. 30 2023 -0.18 -0.21 -1.98 Missed -839.5 This summary was machine generated August 1 at 20:21 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com) ### Related Stocks - [ARCT.US - Arcturus Therapeutics](https://longbridge.com/en/quote/ARCT.US.md) ## Related News & Research | Title | Description | URL | |-------|-------------|-----| | Arcturus Therapeutics Spotlights Inhaled mRNA CF Phase 2b Plan, FDA Talks for OTC Program at Summit | Arcturus Therapeutics (NASDAQ:ARCT) presented at Guggenheim’s 2026 Emerging Outlook Biotech Summit, highlighting its mRN | [Link](https://longbridge.com/en/news/275642293.md) | | ArcticZymes Technologies Hosts Capital Markets Day to Showcase Enzyme Platform Expansion | ArcticZymes Technologies ASA will host its Capital Markets Day 2026 in Stockholm, focusing on scaling its enzyme platfor | [Link](https://longbridge.com/en/news/275569710.md) | | Arcturus Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference \| ARCT Stock News | Arcturus Therapeutics Holdings Inc. (Nasdaq: ARCT) announced that CEO Joseph Payne will present at the 44th Annual J.P. | [Link](https://longbridge.com/en/news/271992613.md) | | Arcturus Therapeutics Maps Near-Term Milestones for CF mRNA Therapy, ARCT-810 at J.P. Morgan Conference | Arcturus Therapeutics CEO Joe Payne presented the company's focus on mRNA therapeutics at the J.P. Morgan Conference, hi | [Link](https://longbridge.com/en/news/272352451.md) | | Arcturus Therapeutics Updates CFO Severance and Stock Option Terms | Arcturus Therapeutics Holdings Inc. announced no changes to CFO Daniel Roberts' compensation terms. His employment agree | [Link](https://longbridge.com/en/news/269725945.md) | --- > **Disclaimer**: This article is for reference only and does not constitute any investment advice.